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 ABSTRACT  
Introduction: The purpose of this study was to investigate the role of brain blood 
flow (BBF) on respiratory control during exercise-induced increases in body temperature.  
BBF is controlled largely by vascular responses to metabolic demand and arterial blood 
hydrostatic and carbon dioxide pressures.  It has recently been found that hyperventilation 
occurs in response to a small rise in core temperature (Tc) during exercise, irrespective of 
exercise intensity, but potentially dependent on aerobic fitness.  This ventilation drive appears 
to be independent from the aforementioned determinants of BBF.  Furthermore, some of the 
vascular control of BBF is mediated by prostaglandins; impairing their production (e.g., 
pharmacologically, using Indomethacin) can reduce BBF.  The effect of prostaglandins on 
brain blood flow and thus on thermoregulatory and ventilation drive during moderate to high 
intensity exercise is not known.  This study tested the hypothesis that prostaglandin-mediated 
reductions in BBF would reduce the Tc thresholds for hyperventilation during exercise, 
thereby demonstrating the critical importance of BBF for ventilatory control in exercise.  It 
was further hypothesised that trained individuals would show an absence of respiratory 
thresholds with normal BBF during exercise, but that these thresholds would become evident 
with Indomethacin-reduced BBF. 
 
Methods: A single-blinded, randomised crossover design was used, with nine male 
participants spanning a wide range of aerobic power (42 – 75 mL . kg-1 . min-1).  After an 
initial familiarisation session, participants undertook four testing sessions; two with ingestion 
of  1 g cornflour (CONTROL), and two with ingestion of an equivalent-looking pill 
containing 100 mg Indomethacin (INDO), 90 min before exercise. During the 90-min rest 
period, cerebrovascular reactivity, heart rate and Tc were measured alongside Middle 
Cerebral Artery velocity (MCAv) as a measure of BBF.  Participants then completed (i) 
prolonged cycling at a standardised workload (40% V̇O2max) or (ii) ramped exercise to 
exhaustion (20 W per minute), thereby making four sessions.  Paired t-tests were used to 
compare respiratory thresholds and slopes as functions of Tb and MCAv within each form of 
exercise, whereas two-way repeated measures ANOVAs were used to examine time-related 








Results: MCAv was reduced by ~32% with INDO compared to CONTROL at rest 
(39  6 vs. 57  10 cm.s-1) and during steady state exercise (42  6 vs. 64  7 cm.s-1). Despite 
the marked reduction in MCAv, this had minimal impact on thresholds for ventilatory 
parameters (i.e. V̇E, V̇O2, V̇E/ V̇CO2, V̇E/ V̇O2, respiratory frequency or tidal volume, except 
for a possible small reduction in PETCO2 with INDO (39  2 mm Hg) vs. CONTROL (40  2 
mm Hg; 95%CI of the difference: -1  1 mm Hg; p=0.08)., whilst ventilatory parameters 
were unaltered and there was not a reliable presence of thresholds, which lead to not being 
able to formally test. 
 
Conclusion: Marked reduction in MCAv, by way of Indomethacin, had minimal 
effect on ventilatory responses during exercise, indicating that MCAv per se is not a major 
factor in the control of ventilation during exercise (e.g., via its effects on H+ concentration or 
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The brain controls many physiological functions, such as breathing and 
thermoregulation. Thermoregulation is controlled largely by the preoptic region of the 
anterior hypothalamus (POAH). Neurons within the POAH are temperature sensitive, 
resulting in behavioural and thermoregulatory responses (Nybo, 2007).  Respiratory control in 
exercise is driven by the motor cortex in conjunction with a multitude of other inputs, 
particularly chemoreceptors situated within the medulla of the brain and carotid and aortic 
bodies responding to alterations in CO2 and O2 pressures in arterial blood (Mohan & Duffin, 
1997; Somers, Mark, & Abboud, 1991).  Both the control of respiration and thermoregulation 
are influenced by alterations in brain blood flow (BBF). 
 
The brain’s demand for blood supply is higher than any other organ, and accounts for 
12-15% of cardiac output at rest despite being only ~2% of body mass (Nybo, 2007; Tameem 
& Krovvidi, 2013).  Blood supply to the brain is via the carotid and vertebral arteries and 
returned via the jugular veins.  Control of BBF can be attributed to myogenic responses, 
blood gas pressures, metabolic demand and subsequent changes in carbon dioxide and 
oxygen levels locally.  Unlike blood supply to most tissues and organs, BBF must be 
relatively stable to maintain (optimal) brain function.  Stabilisation of BBF is achieved via a 
multitude of physiological interactions such as: blood pressure (BP), cardiac output (˙Q), 
partial pressure of arterial carbon dioxide (PaCO2), and brain metabolism (Ainslie & Duffin, 
2009; Willie, Tzeng, Fisher, & Ainslie, 2014), in an attempt to prevent hypo or hyper 
perfusion.  
Alterations in BBF appear to have an important role in stabilising (and also 
destabilising) respiratory control during fluctuating levels of chemical stimuli.  When BBF 
increases, hydrogen ions are washed out from the central chemoreceptors, reducing their local 
concentration [H
+






thus increases ventilation via greater [H
+
]-induced stimulation of the chemoreceptors. 
However, increased ventilation can also result from a small rise in brain temperature (Tb) 
(Nybo, 2007).  The onset of this hyperthermic-induced hyperventilation seems to be 
markedly higher at rest than during exercise (Fujii et al., 2008; Tsuji et al., 2012).  The lower 
onset threshold in exercise occurs even during light exercise, (Fujii et al., 2008; Hayashi et 
al., 2011), which is interesting because it seems unexplainable by differences in [H+] in the 
systemic circulation or locally.  Preliminary data from Hayashi et al., 2011, indicate that this 
ventilatory threshold occurs at a much higher Tc in trained than untrained individuals.  With 
other myogenic and metabolic factors being controlled, it is likely that at lower exercise 
intensities, the increased ventilation is directly related to increased Tc per se interacting with 
the motor command.  Interestingly, an increase in Tc is paralleled by reduced brain blood 
flow (BBF), which is thought to increase ventilation through increased chemoreceptor 
sensitivity to CO2 and to a lesser extent O2 (Fujii et al., 2008). 
Some pharmacological agents, including those used routinely at rest and in exercise, 
also alter BBF. For example, the Non-Steroidal Anti-Inflammatory Drug (NSAID) 
Indomethacin (INDO), reduces BBF substantially (Fan et al., 2011; Xie, Skatrud, Puleo, & 
Dempsey, 2006).  NSAIDs do so by inhibiting the production of prostaglandins, by 
inhibiting an enzyme that leads to their formation i.e., cyclo-oxygenase (COX). However, 
the effect that INDO has on BBF and thus also on thermoregulatory and ventilatory drive 
during exercise is not yet well understood.  Examining the interaction among BBF, 
thermoregulation and ventilation may be an essential component needed for understanding 






The main aim of this thesis was to determine the role of BBF on thermoregulatory 
and respiratory control during exercise.  BBF was indexed using velocity of the Middle 
Cerebral Artery flow (MCAv), which was pharmacologically-reduced using a non-specific 
NSAID.  Incremental and steady-state exercise bouts were then undertaken with and without 
reduced MCAv (and presumably also altered brain temperature) to determine its role in 
controlling ventilation during exercise. 
1.1.1. The research questions were: 
 
1.  Is the Tc threshold for heat-induced hyperventilation affected by BBF?  





It was hypothesised that: 
1. An INDO-induced reduction in BBF will reduce the ventilatory threshold 
during steady-state and ramped exercise.  If this hypothesis was accepted, it 
would indicate that brain temperature and/or its [H+] is interacting with 
central command to stimulate ventilatory drive during exercise. 
2. Trained individuals will show an absence of respiratory thresholds with 
normal BBF during exercise, but then show a presence of these thresholds 
with INDO-induced lowering of BBF in steady-state exercise.  If this 
hypothesis was accepted, it would indicate that trained individuals can 







2.1 BRAIN BLOOD FLOW 
The brain’s relative demand for blood supply is higher than any other organ, and 
accounts for 12-15% of cardiac output at rest (Tameem & Krovvidi, 2013).  Despite the brain 
representing a mere 2% of total body weight, it requires 20% of total oxygen whilst at rest, 
with a normal basal rate of a 1400 g brain being ~50 mL O2/min; this is quite astounding 
considering the average basal metabolic rate of oxygen for a 70 kg male is ~250 mL/min  
(Ainslie & Duffin, 2009).  Blood supply to the brain is via the vertebral and internal carotid 
arteries; these main arteries form the Circle of Willis, which allows for the distribution of 
Brain Blood Flow (BBF).  Return of blood occurs largely via the jugular veins, which are 
situated parallel to the carotid arteries (Tameem & Krovvidi, 2013).  The cerebral tissues’ 
limited storage capacity for oxygen and energy substrates requires a constant and high 
reliance on substrate delivery to ensure that metabolic and neurological demands are met.  
Stabilisation of BBF is achieved via a multitude of physiological interactions, such as, 
blood pressure (BP); cardiac output (˙Q); partial pressure of arterial carbon dioxide (PaCO2), 
and brain activity (Ainslie & Duffin, 2009; Willie et al., 2014).  Regulation of BBF is 
determined by the balance of neuronal metabolic demands and regulation of blood flow from 
the systemic circulation; preventing hypo or hyper perfusion in the brain despite changes in 
systemic blood flow, pressure and gas pressures (Ogoh & Ainslie, 2009).   
Cerebral perfusion is determined ultimately by the driving pressure - cerebral 
perfusion pressure (CPP) - and the resistance to that pressure; intracranial pressure (ICP) and 
cerebral vasculature resistance (CVR). With CPP being the pressure difference between 
arterial and venous circulation of blood flow, with a normative range between 70-90 mm Hg 
in adults (Tameem & Krovvidi, 2013).  Within this CPP range, BBF is regulated via the 
myogenic ‘auto regulation’ of cerebral vessel tone.  In addition, CPP is reliant on other 
factors to ensure satisfactory perfusion to cerebral tissue, such as heat, endothelial function 
and arterial gas content.  Intracranial pressure (ICP) is the pressure within the skull; it is 
determined by brain volume, blood and cerebrospinal fluid (CSF) pressures.  In a supine 
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healthy adult,  ICP is 5-15 mm Hg, and is lower when standing (Tameem & Krovvidi, 2013). 
The CVR is critical when discussing variance of BBF at rest and during exercise and refers to 
the calibre of the vessel(s) and the subsequent resistance to blood flow within the particular 
vessel(s).  Increased resistance is concomitant with vasoconstriction and subsequently 
reduced BBF, and vice versa (Tameem & Krovvidi, 2013).  Finally, it is important to 
acknowledge that changes in mean arterial pressure (MAP) and central venous pressure 
(CVP) will directly influence changes in BBF through increases or decreases of CPP, ICP 
and CVP, during rest and exercise.  
2.1.1. Chemical regulation  
 
Brain vasculature is very sensitive to alterations in PaCO2 and to a lesser extent PaO2. 
PaCO2 is a potent factor of BBF, with a 3-6% increase, or 1-3% decrease, in BBF flow per 
mm Hg change in PaCO2 above, or below, the resting (eucapnic) value (Sato et al., 2012; 
Willie et al., 2012; Willie et al., 2014).  BBF is relatively unaffected by alterations in PaO2 
until <50 mm Hg, whereupon a 1 mm Hg decrease can alter BBF by 0.5-2.5% (Mardimae et 
al., 2012; Willie et al., 2014).   
Hypercapnia (PaCO2, 40-100 mm Hg) is an increase in PaCO2 concentration (Ide & 
Secher, 2000).  A rise in PaCO2 results in cerebral arteriole vasodilatation and increased BBF 
to improve metabolic washout (Fujii et al., 2008).  An increase in PaCO2 results in increased 
hydrogen ion (H+) concentration, which drives an increased central chemoreceptor response 
(Ainslie & Duffin, 2009).  This stimulation of the chemoreceptors drives an increase in 
ventilation, via increased tidal volume and breathing frequency (Hayashi et al., 2011).  
Increased ventilation allows for stabilisation of alveoli O2 pressure, improving haemoglobin 
saturation, and an increased PO2 that aids tissue metabolism along with the removal of CO2 
during expiration (McKay, Evans, Frackowiak, & Corfield, 2003). Subsequent flow-on 
effects from hypercapnia are seen systemically, with an increase in cardiac output, an 
elevation in arterial blood pressure and peripheral myogenic responses (Rasmussen et al., 
1978). 
Hypocapnia (PaCO2 < ~40 mm Hg) causes cerebral vasculature constriction to 
prevent further reductions in PaCO2 and ultimately pH balance in the brain (Ainslie & 
Duffin, 2009).  Thus, a decline in PaCO2 and the subsequent reduced BBF, results in 
decreased O2 delivery to the cerebral tissue.  Hypocapnia can result from over-breathing 
beyond metabolic requirements, known as hyperventilation, which increases alveolar 
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ventilation sufficiently to reduce PaCO2 (Ogoh & Ainslie, 2009).  Anaerobic and aerobic 
metabolism both produce CO2  that results in increased central and peripheral chemoreceptor 
activation, thus altering central and peripheral tissue metabolism, providing information to 
the respiratory centre within the brain stem (Duffin & McAvoy, 1988; Mohan & Duffin, 
1997). 
2.1.2.Cerebral autoregulation  
 
Cerebral autoregulation (CA) is an important determinant of BBF and has 
traditionally been considered to entail two forms; static and dynamic regulation.  Static CA 
describes the regulation of BBF in response to steady changes in blood pressure (BP), while 
dynamic regulation occurs in response to rapid shifts in BP, as seen in rapid postural changes 
(Lind-Holst et al., 2011).  Regardless, both the static and dynamic CA responses ensure CVR 
is corrected to allow adequate BBF and CPP.  Importantly, and recently highlighted by Willie 
et al., (2014), the actual myogenic vascular response that is CA, is the same for dynamic and 
static regulation, regardless of response time. CA is a rapid process (1-10 s response time), 
but can be impaired by various stimuli such as PaCO2, sympathetic nerve activity and 
pharmacological agents (Ogawa et al., 2008; Willie et al., 2014). 
An increase in MAP results in increased vascular tension stimulating depolarisation of 
the smooth muscle and subsequently less constriction of precapillary resistance vessels, 
whereas reduction of MAP is paralleled with vasoconstriction (Aaslid, Lindegaard, 
Sorteberg, & Nornes, 1989; Tameem & Krovvidi, 2013).   
 
2.1.3. Brain blood flow during exercise 
 
Exercise alters many key physiological factors that regulate BBF, in particular 
heightened cerebral neuronal and metabolic activity, along with increased MAP and changes 
(both increases and decreases) in PaCO2  (Secher, Seifert, & Van Lieshout, 2008).  There is a 
rise in BBF until 60-70% V̇O2max, where above the anaerobic threshold and the concomitant 
hyperventilation returns BBF towards resting values, at least for cycling (Ogoh & Ainslie, 
2009), but potentially not for rowing (Faull et al., 2016).  An increase in MAP will increase 
systemic circulation due to increased arteriole wall tension and subsequently altered local 
metabolic activity (Ide & Secher, 2000). Increased SNSA can potentially constrain BBF via 
direct constriction of alpha adrenoreceptors in arterioles, and may also be modified by PNS 
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activity, which is inhibited with increasing intensity of exercise.  Consequently BBF 
regulation during exercise, is determined by the balance between levels of various regulatory 
mechanisms (such as PaCO2 and MAP). 
2.1.4. Brain blood flow and Heat 
 
Passive heating increases CVR and subsequently causes a decline in BBF, which is 
associated with an impairment of orthostatic tolerance (Wilson, Cui, Zhang, & Crandall, 
2006).  A high proportion (~50%) of the reduction of BBF during heating is attributed to 
hyperthermic hyperventilation, and the subsequent reductions in PaCO2 causing hypocapnia 
and thus vasoconstriction (Fan et al., 2008; Nelson et al., 2011).  As such, other contributors 
to reduced BBF during heating have yet to be fully understood.  Redistribution of cardiac 
output or cerebral vasoconstriction due to heightened sympathetic activation were speculated 
to attenuate BBF in the heat (Brothers, Zhang, Wingo, Hubing, & Crandall, 2009; Fan et al., 
2008), however studies have shown that altered cardiac output does not alter BBF in passive 
heating (Fan et al., 2008; Nelson et al., 2011).  Nelson et al. (2011) concluded the reduction 
in BBF was linked to alterations in stroke volume and end diastolic pressure, thus indicating 
baroreceptor and pressure-passive influences on BBF during passive heating.  Other research 
has indicated that increased Tc reduces motor cortex output, thereby attenuating muscle 
recruitment and metabolic heat production, ultimately indicating that BBF attenuation 
correlates positively with reduced motor cortex output (Ross et al., 2012).  
 
2.2 RESPIRATORY  
Ventilation is controlled by several factors during exercise, including chemical and 
mechanical input from activated muscles, central and peripheral chemoreceptors, various 
lung and airway receptors, and especially output from central command (now defined as a 
feedforward mechanism involving parallel activation of respiratory and cardiovascular 
centers in response to motor cortical activation of muscle).(Rasmussen et al, 1965; Hayashi et 
al, 2005). Thus leading to hyperventilation occurring when increased ventilation exceeds 
metabolic needs, Because the centres controlling breathing reside in the brain, brain 
temperature and pH regulation are interdependent on BBF for stability (Hayashi et al, 2005).  
Higher brain temperature increases neuronal activity of the respiratory centre, indicating that 
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an increase in ventilation is directly influenced by brain temperature during both rest and 
exercise (Cabanac & White, 1995; Baker et al, 2009; Tsuji et al, 2012). 
 
Tc-induced hyperpnoea (increased ventilation matched metabolically) in most species 
serves the purpose of offloading heat via evaporation from the airways (Roberston, 2006).  
This phenomenon was considered to exist in humans, suggesting that the hyperthermic-
induced hyperventilation response is a thermoregulatory response and may protect against 
rising brain temperature (i.e., selective brain cooling) (White et al, 2010).  White et al. (2010) 
suggested the rise in brain temperature in combination with increased ventilation, helps 
offload heat via convective and especially evaporative heat exchange in the upper respiratory 
tract.  As Nybo (2008) and others point out, however, the transit time of blood during 
exercise is too fast to allow adequate heat offload, given that humans do not possess the 
specialised heat-exchange vasculature (carotid artery) that provides for this in some other 
mammals.  Tsuji et al (2012) have further questioned selective brain cooling via 
hyperthermic-induced hyperventilation, highlighting that the rise in ventilation will elicit a 
cerebral hypocapnic-induced vasoconstriction response, resulting in increased brain 
temperature and respiratory alkalosis via the reduced blood flow.  Thus, unlike panting in 
other mammals, humans appear to suffer from true hyperventilation under heat stress. 
Landis et al (1926) and White and Cabanac (1996) reported findings showing that a 
faster rate of rise of Tc induced a rapid increase in minute ventilation, which was considered 
to be supportive of brain cooling.  As such, both research groups used rapid increases in 
workload to increase heat production and Tc more rapidly.  A major confounding factor with 
progressive exercise however, is the central command and muscle receptor input to 
ventilation, so it becomes difficult to delineate if an increase in Tc will drive a ventilation 
increase exclusively.  It seems more likely that the rise in ventilation was stimulated by these 
central and peripheral factors, rather than a rise in heat production via metabolic heat 
production during the bouts of exercise. 
 
Hayashi et al. (2004) reported that post-exercise lower-limb cooling reduced Tc and 
skin temperature (Tsk), which was paralleled by a decline in ventilation.  However, it was 
unclear as to the effect of Tc or Tsk on the modulation of ventilation.  Therefore, Hayashi et 
al. (2006) hypothesised that Tsk would initiate a peripheral thermoreceptor response, thus 
activating a negative feedback loop.  However, Tc appeared to have a more direct influence 
than Tsk on ventilation, which was interpreted as support for a central command feedforward 
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mechanism controlling ventilation during moderate exercise.  To investigate this hypothesis, 
recreationally-active participants (n = 13, V̇O2peak 48 mL . kg-1 . min-1) cycled at 50% V̇O2max  
for 60 min or to volitional exhaustion, in a water-perfused suit at three temperatures (10°C, 
35°C and 45°C) in an attempt to delineate the role of Tc and Tsk on hyperthermic-
hyperventilation modulation. The effect of Tsk on hyperthermic hyperventilation and Tc was 
minimal, from which it was concluded that ventilation was more influenced primarily by 
rising Tc and central command. 
 
Tsuji et al. (2012) examined the effect of passive and active heating on the 
hyperthermic-hyperventilation threshold. Using a cross-over design, healthy male participants 
(n= 12, V̇O2peak 50 ± 6 mL 
. kg-1 . min-1) either rested (lower-body water-perfused suit; 47-
48°C) or cycled (37°C ambient, 50% RH) at 25% and 50% of V̇O2peak. Trials ceased once 
core temperature reached 39°C or participants reached volitional exhaustion.  Hyperthermic 
hyperventilation was determined as an increase in minute ventilation, respiratory frequency 
and a decline in end-tidal carbon dioxide and tidal volume.  Its threshold and sensitivity (Δ 
V̇O2peak relative to ΔTc) were at a lower Tc in 50% V̇O2peak exercise in comparison to passive 
heating, whereas neither threshold nor sensitivity differed between 25% and 50% V̇O2peak 
exercise.  Thus, exercise per se lowered the threshold for heat-induced hyperventilation.  
Importantly, with their experimental design, Tsuji et al. (2012) established thermal effects on 
ventilation with minimal metabolic disruption from exercise, subsequently minimising any 
metabolic factors altering ventilation thus concluding that ventilation increases were directly 
affected by the Tc rise during exercise, and were also apparent at a lower Tc than occurs 
during passive heat stress (Tsuji et al., 2012). 
 
2.3. THERMOREGULATION 
Human core temperature (Tc) is tightly regulated within a restrictive range of ~0.2 - 
0.3°C from a given point (Mackowiak, 1998) often near 37.0°C, while a deviation of 3.5°C 
can result in physiological impairment and even fatality (Lim, Byrne, & Lee, 2008).  The Tc 
fluctuates 0.5-1°C over a 24-hour period, with a peak occurring in late afternoon and nadir 
early morning (Cabanac & Massonnet, 1974).  Many researchers have supported the primary 
involvement of the hypothalamus, specifically the preoptic/anterior area as the primary 
thermosensitive area within the central nervous system (CNS) (Romanovsky, 2007b).  Other 
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areas of the CNS have also been identified as providing critical roles in thermoregulation, 
namely the dorsomedial nucleus of the hypothalamus, periaqueductal grey matter of the 
midbrain and the nucleus raphe pallidus in the medulla (Benarroch, 2007).  Thermal input is 
from two main sets of thermoreceptors; central thermoreceptors, some of which reside within 
the hypothalamus itself and monitor the temperature of the blood as it passes through the 
brain, and peripheral receptors in the skin monitoring the external temperature changes 
(Romanovsky, 2007a). The central receptors are primarily warm sensitive whereas the 
peripheral ones are primarily cold sensitive. 
2.3.1. Heat Regulation 
  
When heat gain is equal to heat loss, Tc is stable.  A rise in heat gain will 
subsequently increase Tc and drive the necessary physiological reactions to dissipate heat via 
conduction, convection, radiation or evaporation, and restore appropriate Tc.  Heat sources 
that can result in a rise in Tc can be from environmental or via metabolic reactions.  
Conductance is internal transfer of heat from an organ or muscle into the blood where 
it can then be relocated to the outer extremities of the body and off-loaded to an object or 
clothing, or vice versa.  Convection is the process of exchanging heat through the movement 
of air or water molecules across the skin; convection relies on dilation of skin vasculature and 
muscle to allow for increased blood flow to the periphery.  Heat loss will depend on 
vasomotor tone and also the rate of air or water flow.  Radiation is the exchange of heat 
through the transfer of infrared rays.  Finally, evaporation is the most powerful heat loss 
mechanism for humans.  Heat within the body is conveyed from the blood to the skin, where 
it is absorbed into water molecules as they vaporise and move into the atmosphere.  Each 
gram of vaporised sweat will absorb 2.43 kJ of heat.  The sweating response is induced 
mainly by increased Tc and by, to a lesser extent, thermal input from the skin (Frank, Raja, 
Bulcao, & Goldstein, 1999; Nadel, Bullard, & Stolwijk, 1971; Wyss, Brengelmann, Johnson, 
Rowell, & Niederberger, 1974). 
The body’s inability to dissipate heat will result in a continued rise of Tc and 
subsequently result in hyperthermia.  Whereas, cooling of Tc will inhibit warm sensitive 
receptors in the preoptic anterior hypothalamus, resulting in a heat gain response.  
Sympathetic activation is stimulated by cold receptors eliciting adrenergic activity, 
subsequently altering cardiovascular control and vasoconstriction of peripheral vessels to 
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limit heat loss.  The redirection of blood flow is to ensure heat is returned to the core to 
minimise any further drop in Tc, due to cool blood returning from peripheral tissue.  
Cardiovascular control and vasomotor tone are vital responses to ensure heat retention. 
During negative heat balance, the initial defence is by activation of alpha-
adrenoreceptors in cutaneous and underlying vasculature, to minimise convective and mass 
flow transfer of heat to the skin. With more substantive cooling, muscle contractions in 
antagonist muscles (i.e., shivering) will occur to produce heat.  Work conducted by 
Giesbrecht et al (1997) discusses the importance of the shivering response to produce 
endogenous heat and subsequently raise Tc.  Intravenous injection (1.5 mg/kg) of Meperidine 
(opioid pain medication) was given to eight male participants who were cooled in water (8oC) 
until a mild hypothermic state was achieved.  Participants were then placed in a sleeping bag 
to begin the re-warming phase.  Meperidine abolished the shivering response and 
subsequently resulted in a significant after drop of Tc when compared to control treatment.  
Another important aspect to heat gain is non-shivering thermogenesis, which is 
independent of muscle activation (Jansky, 1979).  Reduction in Tc results in increased 
thyroxin secretion and catecholamine release, in particular noradrenaline, which causes the 
release of free fatty acids resulting in increased metabolic heat production through increased 
cellular metabolism (Vybiral, Lesna, Jansky, & Zeman, 2000).   
Whilst these autonomic response are important for thermoregulation. Behaviour 
thermoregulation is more powerful in response to heat and cold, albeit more complex to 
understand. An example is exercise, where intensity can be concisely increased or decreased 
in an attempt to offload or gain heat. 
2.3.2. Thermoregulation onset 
 
The onset of thermoregulation has long been debated, with some researchers 
supporting a set-point theory and others suggesting a null-zone hypothesis.  The set-point 
theory was presented by Hammel in 1963.  Hammel’s model presents thermoregulation using 
a set-point signal as a comparator for body temperature; a corrective response is executed 
when body temperature differs from the comparator signal.  Cabanac (2006) further describes 
the set-point theory as comparing the difference between an actual temperature and a set-
point that is desired by the organism, governed by an error signal.  Error signals evoke 
effector responses to combat the deviation from the set-point; e.g., if Tc rises, regulation is 
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invoked to combat the hyperthermia (e.g., sweating), and vice versa.  Cabanac and Massonnet 
(1977) reported results to support a set-point in thermoregulation control within humans.  To 
illustrate the set-point, sweat and shivering responses were evoked in participants via 
immersion in 38oC water (sweat response) then cooled in 28oC water (shiver response) in 
attempting to delineate a set-point.  Although there was a reported non-significant overlap 
between sweating and shivering onsets, the authors still concluded that a set-point was 
evident.  Furthermore, Mekjavic et al. (1991) reported an overlap between sweat onset and 
shivering response, reinforcing the set-point theory, and concluding there was no “null-zone” 
observed.  Cabanac (2006) questioned the findings reported by Mekjavic et al. (1991) on the 
basis that rectal and oesophageal measures were used and the overlap could be due to the 
slow change in temperature of the tissue surrounding the thermistors, and there could be a 
minute “null-zone” differentiating the onsets.  Cabanac (2006) further argued that due to 
neither measure being considered to reflect brain temperature, it is difficult to confirm either 
the existence or non-existence of a “set-point”, whereas he suggested that tympanic 
temperature may be a better reflection of brain temperature.  
A null-zone is believed to occur until temperature either drops below or rises above 
the set-zone and heat gain or loss, respectively, will increase in an attempt to rectify any 
thermal perturbation.  The null-zone hypothesis for thermoregulation in humans has been 
difficult to establish.  Mekjavic et al (1991) discusses the difficulty in testing for a null-zone, 
as cooling Tc at various temperatures alter internal temperature gradients and therefore affect 
afferent signalling.  
 
 A more contemporary view is one that proposes warm sensitive and cold sensitive 
thermoreceptors in the periphery and core, act in a Reciprocal Cross-Inhibition (RCI), 
whereby independent sensor-to-effector pathways exist for heat loss and heat production. 
When one pathway is excited or activated, the other is reciprocally inhibited.  These 
pathways could create a point where they would overlap and neither heat loss nor heat gain 
effectors would be active; i.e., a null point at which body temperature is regulated (Bligh, 
1998; Nakamura & Morrison, 2008).  However, the difficulty that such theories face is 
explaining the regulated increase in Tc that occurs under various circumstances such as fever 
(Kluger, 1991), and possibly even exercise itself (Bradford et al., 2007), whereby either no 





2.3.3. Hyperthermia and Exercise 
 
Heat production during exercise comes from the energy released during conversion of 
adenosine triphosphate to adenosine diphosphate, and the metabolic pathways that provide 
for this.  Exercise is the most prevalent, intense thermal perturbation facing humans in 
contemporary societies; hard exercise can generate sufficient heat to potentially elevate body 
temperature by 1°C in 4 min. Increased muscle recruitment and contraction, and resulting 
upregulation of metabolic rate, results in increased heat production and heat storage (Nadel, 
1985).  Furthermore, heat gain from the environment can alter Tc and subsequently dampen 
thermoregulation effectiveness (Brotherhood, 2008).  Due to heat production initially 
exceeding its dissipation, heat storage occurs in the recruited muscles resulting in increased 
muscle temperature, leading to a reversal of the temperature gradient between muscle and 
arterial blood.  Heat is now transferred down this gradient from muscle to blood and 
subsequently to the body core (Wendt et al, 2007).  
 
As mentioned above, increasing Tc causes activation of heat loss mechanisms, in 
attempting to maintain appropriate Tc.  Continued rise in Tc results in hyperthermia (Hales, 
1997).  Hyperthermia can occur due to environmental heat load and/or through exercise.   
 
 Thermoregulatory responses appear to show different stages of effectiveness during 
heat stress.  Firstly, during constant-load exercise, the metabolic heat production will elicit 
sweating and redistribution of blood flow to cutaneous vessels before both effectors plateau 
just above Tc of 38 °C (Nadel et al, 1971).  Next, continued exercise will result in conflict 
between Tc and blood pressure (BP) regulation, which is exacerbated as hyperthermia 
becomes more severe.  Finally, heat loss capacity is severely compromised due to reduced 
central blood volume via peripheral pooling and eventually also sweating, and may be further 
compromised or even counteracted if pyrogenic mediators become activated. 
 
During increased heat production and subsequent heat storage, the thermoeffectors 
response will increase proportionally (Nadel, 1985).  The effector response can be modified 
locally at the skin due to a direct effect on the sweat glands’ response to internal thermal 
drive (Nadal et al, 1971).  Heat loss and heat gain activation thresholds during and following 
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exercise are also determined by non-thermal factors such as mechanoreceptors, 
metaboreceptors, baroreceptors and feed-forward influence from the CNS (Kondo et al, 2010; 
Kenny et al, 2009).  For example, activation of mechano- and metaboreceptors within the 
working muscles can increase sympathetic nervous activity, thereby increasing blood 
pressure and sweat rate (Jackson & Kenny, 2003).  Unloading of the baroreceptors, as occurs 
especially following exercise, leads to vasoconstriction of the cutaneous arterioles, and thus 
higher body heat content and Tc after exercise than at rest before exercise.  During exercise, 
hypohydration can be more prevalent and amplifies this effect, at least partly by exacerbating 
the reduction in CVP and volume and the elevation in plasma osmolarity (Cai et al, 2000; 
Jackson & Kenny, 2003; Kondo et al, 2010).  
2.3.4. Fever 
 
Fever is a complex physiological response that is described as a temporary elevation 
in the body’s thermoregulatory thresholds.  Induction of a fever response is stimulated by 
either exogenous or endogenous pyrogens (Cabanac & Massonnet, 1974; Leon, 2002; 
Mackowiak, 1998); subsequently fever is seen as a systemic inflammatory response to 
infection or trauma (Kluger, 1992).  Fever differs from simple hyperthermia, as hyperthermia 
results from increased heat production and storage exceeding heat dissipation that results in 
body temperature exceeding thresholds.  In contrast, a fever response increases 
thermoregulatory thresholds; new thresholds therefore enable defence of the elevated 
temperature, possibly to allow effective destruction of pathogens (Kluger, 1992; Leon, 2002; 
Mackowiak, 1998) by increasing metabolic rate, which in turn slows the reproduction of 
pathogens (Kluger, 1986, 1992).  Fever is not limited to infection or trauma, as regular 
exercise appears to invoke a fever-like response.  Specifically, exercise-induced heat stress is 
paralleled with elevated sweat thresholds and plasma cytokine concentrations, facilitating 
production of inflammatory prostaglandins (PGs), which is important, as PGE2 can mediate 
fever (Bradford et al., 2007). 
2.3.5. Lipopolysaccharides 
 
The most common pyrogenic endotoxin is Lipopolysaccharide (LPS).  LPS is derived 
from gram-negative bacteria, which are abundant within the gastrointestinal tract.  To 
investigate the fever response, animal-based studies administer LPS as it provides a more 
consistent effect when compared to infectious bacteria.  Indeed, it is well documented that 
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LPS introduced into the circulation propagates a fever response, as the LPS concentration 
exceeds the liver’s potential to clear it, thus triggering fever (Jeukendrup et al., 2000; 
Sakurada & Hales, 1998).  Furthermore, when LPS is confined to the intestinal lumen it 
causes no harm, and even if small quantities pass through into circulation it is not overtly 
dangerous as macrophages in the liver have the ability to remove it from circulation.  
However, fever can develop if the rate of flux of LPS into the circulation exceeds its rate of 
removal (De Bandt, Waligora-Dupriet, & Butel, 2011; Sakurada & Hales, 1998).  
The redistribution of blood during exercise could propagate a fever response.  Blood 
distribution during exercise is hierarchical, which results in inactive or ‘less important’ tissue 
having a diminished blood supply, in particular the kidneys, liver, gut and inactive muscle 
(van Wijck et al., 2011).  Reduced blood flow can cause gut ischaemia and with the 
combined effects of dehydration, hyperthermia and a high proportion of blood being 
redistributed to active muscle and tissue, prolonged ischaemia can mediate gut permeability 
(van Wijck et al., 2011).  Propagation of LPS in the circulation is due to the tight junction of 
the intestinal wall developing increased permeability, allowing for larger molecules such as 
LPS to be transported into interstitial fluid and eventually systemic circulation (Zuhl et al., 
2012). Continuation of LPS leakage into systemic circulation will trigger gastro-intestinal 





Cytokines are pyrogens that mediate fever and inflammation.  Cytokines are released 
from cells during infection, trauma and also during exercise, which then facilitate cellular 
communication and signalling of immune cells (Hanada & Yoshimura, 2002; Petersen & 
Pedersen, 2005).  Cytokines released can be pro-inflammatory, such as Interleukin (IL)-1, IL-
6 and Tumour Necrosis Factor-α (TNF-α), and/or anti-inflammatory, such as IL-1 receptor 
antagonist (IL-1ra), IL-6 and IL-10 (Petersen & Pedersen, 2005).  The function of pro-
inflammatory cytokines involves increased production of PGs and can stimulate or inhibit the 
secondary release of other cytokines.  The pro-inflammatory cascade follows a distinct order 
during infection. The first cytokine released is TNF-α followed by IL-1β, which then 
stimulates IL-6 - which has both pro and anti-inflammatory properties (Petersen & Pedersen, 
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2005).  Interestingly it appears that cytokine release has key differences in exercise compared 
to infection, despite exercise previously having been used as a model of the cytokinesis of 
infection. Specifically, TNF-α and IL-1β concentrations generally do not increase with the 
onset of exercise, with IL-6 appearing to be the first cytokine present in circulation during 
exercise, due to its heightened excretion from muscle contraction and subsequent blockade of 
TNF-α expression (Petersen & Pedersen, 2005).  This is an important consideration as the 
anti-inflammatory cytokines, which modulate inflammation and fever by inhibition of pro-
inflammatory cytokines also includes IL-6, making it difficult to delineate the role of IL-6 
particularly in exercise and fever (Harizi, Corcuff, & Gualde, 2008; Harris, Padilla, Koumas, 
Ray, & Phipps, 2002). 
2.3.7. Cyclo-oxygenase (COX) enzymes  
 
Arachidonic acid is liberated by phospholipase, most commonly phospholipase A2 
(PA2), into its free form through eicosanoid biosynthesis (Zeldin, 2001).  Oxygenation of free 
arachidonic acid results in either hydroexpoxy-enicosatetraenoic acid (HPETE) or 
prostaglandin (PGH2); the latter enzyme is involved in COX regulation.    
Within human tissue there is considered to be two main COX enzymes, COX-1 and 
COX-2 (MiTchell & Warner, 1999).  COX-1 isoform is constitutively expressed in most cells 
and catalyses production of PGs involved in homeostatic control and cell maintenance, 
regulation of renal blood flow and mediating platelet function along with protective 
properties such as those found in the gastrointestinal tract, via gastric mucosa integrity (Vane 
& Botting, 2003). COX-2 is rapidly inducible and reflects heightened activation during fever 
or inflammation, and during basal conditions it is tightly regulated (Vane & Botting, 1998). 
Experiments have confirmed the rapid inducement of COX-2 activation during fever or 
inflammation, due to heightened expression in endothelial cells along with others, after 
simulation with pro-inflammatory cytokines such as IL-1 and TNF-α.  Up-regulation of 
COX-2 is in response to the pathological process characterised by increased local 









2.4. NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used for the 
management of pain and inflammation. The NSAIDs inhibit the activity of COX-1 and/or 
COX-2 and thereby also PG synthesis. Most NSAIDs have been shown to be effective in the 
reduction of fever, due to the inhibition of COX-2 (Simmons, Wagner, & Westover, 2000). 
Gastrointestinal dysfunction has been linked to NSAIDs inhibition of COX-1, and can pose a 
threat to kidney function and BBF as the COX-1 protective mechanism and vasodilatory 
properties are assumed to be compromised (Lippi, Franchini, Guidi, & Kean, 2006), although 
this is not fully understood.  
Indomethacin (INDO) is an effective COX inhibitor and is non-selective, resulting in 
both COX isoforms being inhibited.  In various BBF-related research INDO has been utilised 
due to its unique feature of PG inhibition, and subsequent decreased BBF alongside reduced 
cerebrovascular CO2 reactivity, without changes in metabolic rate or plasma catecholamines 
(Fan et al., 2008; Hohimer, Richardson, Bissonnette, & Machida, 1985; Ivancev et al., 2009).  
Appropriately, BBF and C02 reactivity have been proposed to regulate central pH, therefore 
affecting an important input to respiratory drive (central chemoreceptor stimulus) (Chapman, 
Santiago, & Edelman, 1979; Hohimer et al., 1985).  
In addition, the inhibition of COX-1 due to the ingestion of INDO could have severe 
consequences for gut integrity.  Specifically, the inhibition of COX-1 could increase gut 
permeability and cause an increased presence of LPS into circulation, which can be 
exacerbated by exercise.  Furthermore, INDO also exhibits antipyretic properties and could 
mitigate the fever response induced by gut leakage during exercise.  Specifically, INDO has 
been reported to reduce systemic LPS and the central IL-6- and TNF–α-induced febrile 
response, due to the possible COX inhibition (Soares et al., 2011).  As such, it is unclear as to 
the overall effect INDO will have on fever mediation during exercise, as it appears to possess 
properties that could propagate but also reduce fever responses. 
Therefore, INDO provides an interesting scenario for research.  It has the potential to 
attenuate BBF and CO2 reactivity, thus directly influencing ventilatory control.  Whilst the 
18 
 
systemic vasoconstriction due to COX inhibition will reduce systemic blood flow and 
therefore propagate fever via increased gut permeability, yet also directly mitigate fever 
effects by the reduced production of febrile response. 
2.5. TRAINED VS. UNTRAINED 
 
It has been well established that trained individuals will invoke an earlier 
thermoregulatory response, which is paralleled by a greater power to dissipate heat 
(Greenhaff, 1989; Okazaki et al., 2002).  It has been thought that one important aspect of 
trained individuals’ heat-related adaptation to exercise is a plasma volume expansion and thus 
blood volume expansion (i.e., hypervolaemia) (Convertino, 1991; Convertino, Brock, Keil, 
Bernauer, & Greenleaf, 1980; Sawka, Convertino, Eichner, Schnieder, & Young, 2000).  The 
benefit of hypervolaemia during exercise or heat stress is the increased potential for blood 
distribution to muscle, organs and thermoregulation response to ensure adequate metabolism 
and BBF regulation. 
 
 A related benefit was demonstrated by Sakurada and Hales (1998) using trained and 
untrained sheep; they investigated the effects of heat stress on endotoxaemia and what role 
blood flow may play. A marked difference existed between trained and untrained regarding 
blood flow to the brain and gut.  Interestingly, the trained sheep even under heat stress and 
with similar rectal temperatures, had higher blood flow to the gut and brain.  This finding was 
believed to occur at least in part due to the hypervolaemic response attained by the trained 
sheep and therefore a reduced blood flow competition (Sakurada & Hales, 1998).  A similar 
response was seen in humans, with trained individuals showing a lower pyrogenic response 
during exertional heat stress (Selkirk, McLellan, Wright, & Rhind, 2008), although blood 
volume was not the concluded reasoning behind this result, instead it was apparent that 










  The role of BBF on ventilation control has been subjected to limited research and the 
mechanisms are not yet fully understood.  Rising brain temperature generally causes a rise in 
ventilation referred to as hyperthermic hyperventilation, which at least partly drives a 
reduction in BBF. When BBF and its responsiveness is reduced due to PG inhibition via 
INDO, it is not known what will happen to BBF and thus ventilatory control during heat 
stress. Will alterations in VE occur at different BBF values or be directly influenced by Tc. In 
addition, given that trained individuals appear to have a higher blood volume (which likely 
contributes to their higher BBF during exercise), the hyperventilation response may be at 
different Tc values between highly trained and untrained subjects.  To some extent this has 










Nine male recreational athletes (18-33 years) were recruited; four participants failed 
to complete the trials due to oesphageal thermistor intolerance.  Therefore nine participants 
completed all experimental trials. Their characteristics are shown in Table 1.  Participants 
were healthy and were survey-screened for cardiovascular risk factors, musculoskeletal 
problems, and allergies to INDO or other non-steroidal anti-inflammatory drugs (See 
Appendix A).  This study was reviewed and approved by the University of Otago Human 
Ethics Committee (Approval Number H13/062).  
 
Table 1: Individual characteristics of 9 male participants. 
Participant Age Mass Height BMI V̇O2max 
   (Years) (kg)  (cm)  (kg/m2) (mL·kg-1·min-1) 
A 31 78 179.5 24 50 
B 33 94 181 29 47 
C 25 89 181.5 27 54 
F 23 84 182 25 53 
H 20 84 193 23 54 
I 19 97 196 25 42 
J 18 78 187 22 75 
K 29 75 186 22 59 
L 23 82 182 25 57 
Mean 25 85 185 25 54 
± SD 5 8 6 2 8 




3.2 DESIGN AND PROCEDURES 
3.2.1. Design:  
 
A single-blinded, randomised crossover design was used.  After a familiarisation 
session , participants completed two identical testing sessions (steady-state then V̇O2max 
tests), differing only in whether they ingested placebo (1 g Cornflour) or NSAID (100 mg 
INDO) 90-min prior to exercise.  The ambient air conditions for each trial were maintained at 
35°C with a relative humidity of 60% during exercise, and at 23°C with a relative humidity of 
38  2% during resting.  Each participant completed their test at a similar time each day 
(within 1 hour), with at least 7 days between each trial.  Participants were asked to maintain a 
similar diet and exercise regime prior to the testing period, as well as refraining from 
strenuous exercise, caffeine and NSAID or other analgesic medicine in the 24 h prior to 
testing, and to arrive at the laboratory euhydrated.  
 
 
Figure 1: Schematic of each trial protocol completed by participants. Participants did steady 















































3.2.2. Familiarisation testing 
 
A familiarisation session was conducted to introduce participants to the experimental 
protocol, measurements and exercise requirements of the study.  In this session participants 
also completed a cycling V̇O2max test, as described below.   
3.2.3. Cycling, V̇O2max testing 
 
Each participant completed two V̇O2max tests on a cycling ergometer (Velotron, 
Racermate, USA); with prior ingestion of Indomethacin (100 mg) or CONTROL (Cornflour 
1 g) in a randomised order.  Prior to the test, body mass and height were recorded along with 
24-h diet recall.  Bike set up was based on participant comfort.  Participants were fitted with a 
heart rate monitor, core temperature thermistor (oesophageal), Near Infrared Spectroscopy 
(NIRS), transcranial Doppler and a leak-free mask (Hans-Rudolph, Kansas City, USA).  A 5-
min warm up at 100 W preceded the test, with workload then incrementing at 0.333 W per 
second (20 W per minute) until voluntary exhaustion.  Tests were conducted in ambient 
conditions of 23  0.7 °C, with 39  0.7% relative humidity.  Each participant completed 
their test at a similar time of day (within 1 hour). 
The V̇O2max was measured from the inspired and expired volume, and O2 and CO2 
concentrations in those volumes (Cosmed Quark b2 Metabolic Cart, Rome, Italy).  Heart rate 
(Cosmed Quark b2 Metabolic Cart, Rome, Italy) was recorded during each stage to gauge 
progress and identify their individual max.  These measures allowed for sub maximal 
workloads to be determined for the steady state sessions in the main trials, and to gain 
baseline profiles for characterising each group.  A V̇O2max was considered to have occurred 
when two of the following three parameters were reached: at least 95% of age predicated 
heart rate; respiratory exchange ratio above 1.12, or a plateau in oxygen consumption.  Data 




3.2.4. Main trials 
 
On arrival at the laboratory, participants were seated for 10 min prior to giving a 
resting venous blood sample.  Participants then produced a urine sample and were 
instrumented with the core temperature (oesophageal) thermistor and heart rate monitor.  
Body mass was recorded using calibrated scales (DIGI, DI-10, Rice Lake Weighing Systems 
Inc., WI, USA) while wearing dry cycling shorts.  Participants were instrumented with 
transcranial Doppler and NIRS probes (see below) and a leak-free mask.  Baseline values 
were recorded for 5 min, along with baseline psychophysical measures. Participants’ 
cerebrovascular and ventilatory reactivities were then assessed by breathing 5% CO2 gas in 
air (21% O2, 5% CO2, Nitrogen balance) for 3 minutes.  
After these baseline recordings, participants consumed either CONTROL (1 g 
Cornflour) or INDO (100 mg), and rested quietly for 90 min whilst ventilation, middle 
cerebral artery velocity (MCAV), Near-infrared spectroscopy (NIRS) parameters (see below) 
and core temperature were recorded for 2 min every 15 min. During the final 30 min of this 
rest (drug assimilation) period, the participant’s hands and feet were immersed in cool-
temperate water (~25°C) to provide a clear reduction in core temperature prior to onset of 
exercise.  Following this period, participants repeated the cerebrovascular and ventilatory 
reactivity assessment.  
After the rest period, participants had skin thermistors affixed (Section 3.3.1) then 
donned the rest of their cycling attire, consisting of  long sleeved PVC jacket/ full legged 
insulated cycling tights and rubber gloves.  Participants then had the NIRS probes removed to 
enter the heat chamber, where they sat stationary on the cycle ergometer (Velotron, 
Racermate, USA) whilst the transcranial Doppler cable (headset and probes were not moved) 
and NIRS probes were re-applied.  Once measures were obtained and were satisfactory, 
participants commenced cycling at a set workload of 40% VO2 max and continued until 
either: a clear ventilatory threshold was observed; voluntary exhaustion, or their core 
temperature reached 39°C. Main measures were recorded continually throughout exercise, 
whereas psychophysical measures were recorded at 5-min intervals.  
At completion of exercise, clothing was removed and feet immersed in cool-temperate 
water (~25°C), and the heat chamber was turned off and doors opened to help facilitate heat 
loss post-exercise.  A post-exercise blood sample and psychophysical perceptions were taken 
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within 10 ± 2 min.  Participants then exited the chamber and dried off before a nude body 
mass was recorded, and participants were monitored until Tc reduced to near baseline (within 





3.3.1. Core Temperature 
 
Core temperature was measured and monitored using flexible, sterile, and disposable 
thermistors (Mallinckrodt 400 general purpose, Mallinckrodt Medical Inc. St Louis, USA).  
All thermistors were assumed to be accurate and factory calibrated to 0.1°C.  Thermistors 
were inserted by the participants into the oesophagus, at a depth adjacent to the right atrium, 
as estimated by the formula 0.479 x participant sitting height (cm) – 4.44 (Mekjavic & 
Rempel, 1990).  Participants had their own thermistor, which was sterile upon first usage, 
then deep disinfected (Trigene Advance, Medichem) between uses.  Skin temperature was 
recorded using thermistors glued onto the skin on three sites(forehead, right upper arm, right 
quad). Core and Skin temperature was recorded using a DAQPRO data logger (OM- 
DAQPRO-5300, Omega, USA) at 10-s intervals throughout rest and exercising periods. 
 
3.3.2. Brain blood flow velocity 
 
Brain blood flow velocity was measured, as an estimation of global cerebral 
perfusion, using transcranial Doppler box ultrasound sonography (DWL, Compumedics Ltd, 
Germany) of the right middle cerebral artery (i.e., MCAv).  During resting periods, recording 
was intermittent (every 15 min), whereas during exercise it was continuous.  Insonation was 
via the temporal region, superior to the zygomatic arch.  The ultrasound probe was secured 
using and adjustable headpiece.  Photographs of the positioning of the probe along with the 
insonation depth (mm), gain and mean velocity (cm·s-1) were recorded to ensure consistent 
location of insonation between trials.  Compumedics DWL (DWL, Compumedics Lyd, 
Germany) software was used to ensure the correct vessel based on the depth (incorporating 
M-Mode), waveform and velocity of the signal.  Data were collected via an analogue-to-
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digital converter (Powerlab, ADinstruments, Dunedin, New Zealand) connected to a PC 
running LabChart software (Chart v7.0, ADInstruments, Dunedin, New Zealand). 
 
 
3.3.3. Brain Oxygenation 
 
Total oxygenation index (TOI) was measured using NIRS (NIRO-200, Hamamatsu 
Photonics, Hamamatsu, Japan).  A probe was placed on the right side of the forehead midway 
between the eyebrow and the hair-line, and fastened using opaque strapping tape to eradicate 
exogenous light.  Data were collected via the Powerlab connected to a PC running Lab Chart 
software (as above). TOI data were averaged into 10-s periods for analysis. 
 
3.3.4. Respiratory Gases 
 
Respiratory gases were sampled from a leak-free facemask (Hans-Rudolph, Kansas 
City, USA) throughout rest and exercise periods.  Expired air was sampled continuously for 
volume and fraction of CO2 and O2, from which respiratory exchanges were calculated 
(Cosmed Quark B2, Rome, Italy).  Arterial PCO2 was estimated from end tidal PCO2 
(PETCO2) and simultaneously recorded into the Chart software via an analogue-to-digital 
converter (Powerlab, ADinstruments, Dunedin, New Zealand) connected to a PC running 
LabChart software (Chart v7.0, ADInstruments, Dunedin, New Zealand). The volume 
transducer and O2 and CO2 analysers were calibrated prior to each trial using a 3 L syringe 
and alpha-standard calibration gas (BOC Gases, Auckland New Zealand).  
 
3.3.5. Cerebrovascular and Ventilatory reactivity to CO2 
 
Following 5 min of resting data, participants’ inspired slightly elevated levels of CO2 
(5%) for 3 min to elevate CO2 pressure in arterial blood.  Cerebrovascular and ventilatory 
reactivity to CO2 were assessed as the absolute and relative (%) changes (Δ) in BBF velocity 
(cm·s-1) and ventilation (L·min-1) respectively, per unit change in PETCO2 (Δ PETCO2; mm 
Hg).  CO2 was provided from a 150 L Douglas bag and attached with a Y-shaped, two-way 
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non-rebreathe valve (Hans Rudolph 7900).  Alterations in ventilatory reactivity to CO2 were 
recorded using the respiratory gas analysis system (Cosmed Quark B2, Rome, Italy), 
cerebrovascular measures were recorded via the Powerlab and Chart software (as above). 
 
 
3.3.6. Psychophysical measures (See Appendix D) 
 
The psychophysical measures of perceived body temperature (rated on a 1 – 13 scale), 
thermal discomfort (1 – 10), and overall feeling state (-5 to + 5) were collected at rest and at 
5-min intervals during exercise.  Ratings of perceived exertion were recorded using the 15-
point (6 – 20) Borg scale (Borg, 1962).  
3.3.7. Urine Analysis 
 
Urine samples provided by participants before and after each trial were analysed 
immediately for volume (volumetric cylinder) and specific gravity (handheld refractometer, 
Uricon, Atago Ltd, Japan).  
 
3.3.8. Data Analysis 
 
3.3.8.1. Filtering and calculations:  Absolute and relative cerebrovascular reactivity 
were calculated based on data from baseline (3 min) and 5% CO2 breathing (final 1 min) 
filtered into 10 s averages, then divided by baseline CO2 induced changes in MCAv.  
Cerebrovascular reactivity was cross referenced with respiratory changes in PETCO2 over the 
same time periods. 
Respiratory thresholds during steady state exercise were calculated by plotting the 
mean (10 s average) of key respiratory values (V̇E, PETCO2) over rises in core temperature 
(Tc).  Thresholds were considered to have occurred when a deflection point was seen from a 
linear change in respiratory values.  This was conducted by researchers with extensive 
experience and confirmed using objective software (Duffin, rebreathe method). 
3.3.8.2. Statistics: MCAv, ventilation responses, ratings of perceived exertion and 
core temperature slopes and intercepts were compared using paired-sample t-tests and two-
way repeated measures ANOVA to determine effects of NSAID (~altered BBF) and fitness 
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on respiratory control.  These statistical analyses were conducted within Microsoft excel 
(Microsoft Office Excel. 2008) and GraphPad Prisim (GraphPad, San Diego, USA).  The 
magnitude of differences between sessions and fitness was estimated using 95% confidence 






4.1. Resting period 
4.1.1. Cerebrovascular  
 
Middle cerebral artery velocity (MCAv), as an index of brain blood flow, was 
recorded from all 9 participants during seated rest in temperate conditions (INDO 23  2C; 
RH 37  5% vs. CONTROL, 23  2C; RH 40  5%).  Baseline mean MCAv was similar 
between conditions, being 58  12 cm.s-1 in INDO and 54  9 cm.s-1 in CONTROL (mean 
95% CI of difference: 5  8 cm.s-1; p= 0.25; Figure 2). Thereafter, MCAv fell by 18  11 cm.s-
1 during the 90 min following INDO ingestion, but increased marginally, by 2  2 cm.s-1, in 
CONROL (Interaction effect 95% CI: 20  9; p = <0.01; Figures 2 and 3). This effect was 
evident in MCAv during the INDO condition from 60 min into the resting period 
(p=0.04).Total oxygenation index (TOI) was 74  5% at baseline in both conditions and had not 
changed reliably by 90-min after ingestion of INDO or CONTROL (p=0.50; Table 1). 
 
The MCAv reactivity to 5% CO2 was similar between conditions at baseline (p= 0.90; 
but fell by 35% over the 90-min period following ingestion of INDO relative to CONTROL (p= 
0.05; Figure 4).  
4.1.2. Ventilatory Variables  
 
  Ventilation (V̇E) during 90-min resting period was unaffected by ingestion of INDO 
(Table 2; p= 0.80). Neither were any ventilatory parameters affected; V̇E/ V̇CO2, V̇E/ V̇O2, 
tidal volume or respiratory rate (Table 2). 
Mean oxygen Consumption (V̇O2 mL·kg-1·min-1) pre intervention was not 
significantly different (p=1.00) between trials. Furthermore, oxygen consumption was 




















































Figure 2: Group mean and individual middle cerebral arterial blood flow velocity (MCAv) 







Figure 3: Time course of mean change in middle cerebral artery velocity (MCAv) following 
ingestion of INDO or CONTROL or at time 0. Data are mean ±SD responses for n=9. *= 
































































Figure 4: Cerebrovascular reactivity to 5% carbon dioxide, pre intervention (open bar) then 
90-min post intervention (vertical lines) during either INDO or CONTROL. Data are mean 
±SD responses for n=8. *= Significant difference p= 0.05.  





























End-tidal carbon dioxide (PETCO2) absolute values were similar during baseline; 
INDO 34  2 mm Hg and CONTROL was 34  2 mm Hg (95% CI: 2  1 mm Hg; p=0.5). 
There was a tendency for a small reduction in PETCO2 following INDO ingestion but not 
CONTROL, (mean and 95% CI difference: -1  1 mm Hg; p=0.08; Figure 5). Specifically, 5 
of 7 recorded values fell in INDO, compared with 2 of 7 in CONTROL. 
 
 
Figure 5: Group mean and individual End-tidal Carbon dioxide change from pre-intervention 
then 90min post-intervention during either INDO (top) or CONTROL (bottom). Data are 




















































4.1.3. Heart Rate.   
 
Baseline mean HR were of similar values 64  6 beats.min-1 in INDO and 63  8 
beats.min-1 in CONTROL (difference 95% CI: 5  3 beats.min-1; p= 0.25). However, HR fell 
significantly by 5  2 beats.min-1 during the 90 min following INDO, whilst CONTROL had a 































































Figure 6: Group mean and individual Heart Rate change from pre-intervention then 90min 




4.1.4. Thermoregulatory  
 
Core Temperature (Tc) was 36.9   0.2°C, at baseline for both conditions. Throughout the 90-
min rest period the ingestion of INDO had no effect on Tc (p=0.80; Table 2). 
 
Table 2: Resting cardiorespiratory and thermoregulatory measures before and 90-min after 
ingestion of INDO or CONTROL. 
                 CONTROL            INDO 
  Baseline 
∆ From 
Baseline at 
90 min Baseline 
∆ From 
Baseline at 90 
min 
Total Oxygenation Index 
(%) 74 ± 5  3 ± 3  74 ± 5 4 ± 4 
V̇O2  
(mL·kg-1·min-1) 5.0 ± 0.9 0.1 ± 0.6 5.0 ± 1.0 0.4 ± 0.9 
Ventilation Rate           
(L·min-1) 13 ± 2 -1 ± 1 12 ± 2 0 ± 2 
Respiratory Frequency                                                       
(breaths.min-1) 15 ± 4 -2 ± 1 13 ± 3 1 ± 1 
Tidal Volume                        
(mL) 944 ± 290 -153 ± 211 860 ± 113 -189 ± 164 
V̇E/ V̇CO2                                34 ± 2 2 ± 2 34 ± 4 2 ± 2 
V̇E/ V̇O2                         25 ± 3 2 ± 3 23 ± 3 2 ± 1 
Core Temperature                               
(°C) 36.9 ± 0.2 0.1 ± 0.2 36.9 ± 0.2 0 ± 0.2 








4.2. STEADY STATE 
 
Unfortunately due to unforeseen errors in procedures and recording reliability, the following 
secondary variables were inaccurately captured and thus not sufficiently reliable to report for 
the exercise phases: heart rate in exercise, arterial blood pressure, skin temperature and sweat 
rate. 
 4.2.1. Cerebrovascular 
 
Initial MCAv at the start of exercise was significantly different between conditions; 
INDO 42  7 cm.s-1 vs. CONTROL 63  14 cm.s-1 (95% CI: 21  7, Interaction effect p 
<0.001), by design. Furthermore, the slope across the exercising period was significantly 
different between conditions; INDO 1  5 cm.s-1/oC vs. CONTROL -4  7 cm.s-1/oC  (95% CI: 
5  3, main effect: p <0.05). The onset of exercise resulted in MCAv changes for both trials, 
albeit non-significant. Change across INDO declined by 2  11%, whereas CONTROL 
declined by 2  2% cm.s-1/oC ; (p=0.40; Figure 7). Absolute changes were also non-significant 
across each condition (Time effect: p = 0.40). 
The NIRS-derived cortical total oxygenation index was surprisingly unaffected in the face 
of marked changes in MCAv by the ingestion of INDO. The initial TOI at exercise onset was 
similar to baseline values (time effect; p= 0.21), furthermore the slope across the rising Tc was 
also non-significant (time effect; p=0.50; Table 3). 
 
 




Figure 7: Absolute MCAv response to rising core temperature, during either INDO or 
CONTROL, whilst cycling 40% V̇O2max. Data are mean (±SD) responses for n=9. 
 
Figure 8: Change in MCAv in conjunction with rising core temperature, during either INDO 
or CONTROL, whilst cycling 40% V̇O2max. Data are mean (±SD) responses for n=9. 
 
 
4.2.2. Ventilatory Variables  
 
Exercise onset intercept and slope of ventilatory variables were unaffected by INDO 
from baseline (Table 3). Thers was not a reliable presence of thresholds, so wasn't formally 
tested. However PETCO2 intercept at the onset of threshold in exercise was significantly different, 
INDO 35  1 mm Hg vs. CONTROL 37  1 mm Hg (95% CI: 1  0.9, p= 0.01; figure 9). 






















































Both conditions began to decline with time. Furthermore PeTcO2 continued to be non-
significantly lower in INDO than in CONTROL across all time points (p=0.40; Figure 9). 
Relative PETCO2 increased in both conditions from baseline with the onset of exercise 
and subsequent changes in Tc. Both conditions began to decline with Tc rising above a 0.5°C 
increase from baseline. INDO declined by 4%  8 mm Hg below baseline values with a 1°C 
rise in Tc, whilst CONTROL returned to pre exercise values (p=0.40; figure 10), then fell 
below baseline with a 1.5°C rise in Tc. PETCO2 responses to time and rising core temperature 
were evident for all participants at the 40% V̇O2max workload, but individual sensitivity was 





4.2.3. Core Temperature 
 
The ingestion of INDO had trivial effect on Tc, with a slightly lower intercept point. INDO (36.8 
± 0.3°C) vs. CONTROL (37.0 ± 0.3°C; 95% CI: 0.2 ± 0.3; p=0.20; Figure 13). During exercise the 
rate of Tc rise was also similar in both INDO and CONTROL conditions; (0.05 ± 0.01 vs. 0.04 ± 0.01 
°C per minute; difference: p=0.9). Time to either 39°C or volitional exhaustion was slightly shorter 
with INDO; (30 ± 9 min) vs. CONTROL (32 ± 9 min; 95% CI: 4 ± 2 min; p=0.20; Figure 14). 
 
4.2.4. Exertional and Thermal perceptions  
 
INDO ingestion had minimal effect on RPE, with a similar average across the exercising 
period to that for CONTROL (12 ± 1 vs. 11 ± 1, p=0.50; Figure 15). However thermal perceptions 
were significantly affected by INDO. Thermal discomfort was higher in INDO than CONTROL (5 ± 
1 vs. 4 ± 1 Vs; 95% CI of difference: 0 ±1, p=<0.01), as was perceived body temperature (11 ± 1 vs. 
10 ± 1 95% CI: 4 ± 2, P=<0.01). Also overall feeling was also significantly lower (more adverse) in 




Table 3: Ventilatory parameters intercept and slope (as a function of Tc, e.g L.min-1/oC) during 
steady state exercise for INDO and CONTROL.   
  
                     
CONTROL   
                             
INDO   P Value P Value 
  Intercept Slope Intercept Slope (/oC) Intercept Slope 
Ventilation Rate           
(L·min-1) 51 ± 5 17 ± 14 50 ± 9 17 ± 9 0.5 0.9 
Respiratory 
Frequency                                                       
(breaths.min-1) 23 ± 3 7 ± 6 22 ± 4 8 ± 4 0.4 0.5 
Tidal Volume                        
(mL) 514 ± 2 0.1 ± 0.2 510 ± 2 0.1 ± 0.2 0.8 0.3 
V̇E/ V̇CO2       
(mL·min-1)                         34 ± 3 9 ± 6 33 ± 3 9 ± 5 0.4 1.0 
V̇E/ V̇O2      
(mL·min-1)                   29 ± 4 10 ± 9 29 ± 5 10 ± 7 0.5 0.5 
Data mean (SD) for n=9. 






















Figure 9: End tidal carbon dioxide response to rising core temperature, during either INDO 





Figure 10: End tidal carbon dioxide relative response in conjunction with rising core temperature, 
during either INDO or CONTROL, whilst cycling 40% of individuals’ maximal aerobic power. Data are 
mean (SD) for n=9. 




























































































































































































































Figure 11: End tidal carbon dioxide response to rising core temperature whilst exercising at 
40% of each individual’s (A-L) V̇O2max, in either INDO or CONTROL trials. Data are all 





























































































































































































































































Figure 12: Ventilation response to rising core temperature whilst exercising at 40% of 
V̇O2max, in either INDO or CONTROL trials. Data are all individual responses; n=9. 
 
 
Figure 13: Mean core temperature response with  either INDO or CONTROL, cycling 40% 
of individuals’ V̇O2max.  Data are group mean responses for n=9. 




























Figure 14: Group mean and individual exercise cessation point during steady-state exercise 























Figure 15: Mean perceived exertion and thermal comfort and sensation, during either INDO 































































Ratings of Perceived Exertion
























4.3. RAMPED EXERCISE  
4.3.1. Cerebrovascular  
 
Following a 90-min absorption period MCAv was 38% lower with the ingestion of INDO (42 ± 6 
cm.s-1) than placebo CONTROL (64 ± 7 cm.s-1; 95% CI: 7  5; p < 0.01).  During the exercise warm up,  
MCAv rose by 6 ± 6% in INDO and 9 ± 5% in CONTROL (difference: p=0.10). At the onset of the 
ensuing incremental exercise, MCAv intercept was significantly lower in INDO (45 ± 8 cm.s-1) than 
CONTROL (73 ± 12 cm.s1; difference:  95% CI: 28  13; p < 0.01; Figure 16). The slope of MCAv 
relative to wattage during exercise was not significantly affected by INDO 0.01 ± 3 vs -0.48 ± 7 cm.s-
1.min-1; p=0.80).  
 
4.3.2. Ventilation variables 
 
The ingestion of INDO had minimal effect on the ventilatory thresholds (Figure 16). The first 
ventilatory threshold (VT1) was at 245± 23 W in INDO and 247 ± 25 W in CONTROL (p=0.4), while 
VT2 was at 326 ± 28 and 327 ± 26 W, respectively (p= 0.60).  Individual response profiles for 
ventilatory variables and corresponding MCAv showed individual differences but markedly consistent 
responses between INDO and CONTROL within individuals (Figure 16).  
 
4.3.3. Core Temperature 
 
The ingestion of INDO significantly reduced core temperature (intercept: 36.8 ± 0.3°C) vs. CONTROL 
(37.1 ± 0.3°C; 95% CI of difference: -0.2 ± 0.1; p=0.05; Figure 22). The rate of rise of core 
temperature during exercising was not significantly between conditions: 0.004 ± 0.01 vs. 0.004 ± 






Figure 16: Mean Ventilatory and cerebrovascular (MCAv) threshold during V̇O2max ramp 
test. Arrows are indicative of VT 1 and VT 2 with either INDO or CONTROL. Data are 








































































































































































Figure 17: Individual Ventilatory and Cerebrovascular responses during V̇O2max ramp test 

























































































































Figure 18: Individual Ventilatory and Cerebrovascular responses during V̇O2max ramp test 






















































































































Figure 19: Individual Ventilatory and Cerebrovascular responses during V̇O2max ramp test 



















































































































Figure 20: Individual Ventilatory and Cerebrovascular responses during V̇O2max ramp test 





























































Figure 21: Individual Ventilatory and Cerebrovascular responses during V̇O2max ramp test 






Figure 22: Mean core temperature response with INDO and CONTROL during a ramped 
  
˙ V 
O2 max test.  Data are group mean responses for n=7. 
 
 
Figure 23: Individual core temperature responses during a ramped 
  
˙ V O2 max in INDO and 
CONTROL, trials.  Data are individual responses for n=7. 









































































































































































































































































Several lines of evidence indicate that elevated Tc drives an increased respiratory 
response, referred to as hyperthermic hyperventilation (Abbiss, Nosaka, & Laursen, 2007; 
Hayashi et al., 2011). Recent research (Tsuji et al., 2012) showed hyperthermic 
hyperventilation occurring with both passive heating and active/exercise heating, 
independently of any metabolic effect of exercise.  The threshold onset of hyperventilation 
was lower during active heating vs. passive heating.  Furthermore it was observed during 
active heating that thresholds were somewhat dependent on aerobic fitness; the two fittest 
individuals in Tsuji et al.’s study showed no such response.  Their study led us to examine the 
interrelation between brain blood flow (~MCAv), ventilation and thermoregulation during 
both ramped and steady-state of exercise/metabolism (in which Tc steadily rose) across a 
range of aerobic fitness levels, Steady state allowed purely blood flow and therefore 
potentially its effects on brain temperature to become evident without any confounding 
effects from feedforward (motor cortex) or feedback (from muscle and arterial 
chemoreceptors) mechanisms. Whereas, ramped protocol allowed the exercise intensity 
thresholds to be examined directly by way of seeing whether they occurred at same or 
different core temperature with different brain blood flows. MCAv was manipulated in a 
single-blinded manner using INDO. We anticipated that (i) an NSAID-induced reduction in 
MCAv and its responsiveness to CO2 would reduce the ventilatory threshold, and (ii) that 
more highly-trained individuals would show an absence or delay of respiratory thresholds 
with normal MCAv during exercise, but that these thresholds would occur at a lower Tc with 
INDO.  In contrast to our hypotheses, an NSAID (Indomethacin) induced reduction in MCAv 
did not alter ventilatory thresholds during exercise, and fitness had no clear impact on the 









5.1 RESTING PERIOD 
 
The ingestion of 100 mg of INDO reduced MCAv substantially (Figure 2), as 
expected and as shown in numerous studies (Edwards et al., 1990; Fan et al., 2010, 2011; 
Xie, Skatrud, Morgan, et al., 2006).  This occurred in all participants (Figure 2) and was 
independent of aerobic fitness, as would be expected given that it is a PG-mediated 
inhibition.  The decline in MCAv (Figure 3) was linear across the 90 min following ingestion.  
INDO also blunted cerebral reactivity, by almost half when measured at 90 min (Figure 4); 
this reduction was anticipated and also shown previously (Fan et al., 2010, 2011).  The 
reduction in reactivity is attributable to inhibition of PG reducing the ability for endothelial 
cells to respond to changes in PaCO2. 
Interestingly, the INDO-induced reduction in MCAv was sufficiently severe that no 
participant was able to maintain the breathing frequency and depth for the required time to 
complete the hypocapnic reactivity test, due to dizziness, thus data collection was incomplete and 
the data were omitted from the results.  This was unexpected because the participants in the Fan 
et al studies (2010, 2011) were able to complete this procedure.  Blunted hypocapnic reactivity 
would be in accordance with other research (Fan et al., 2010) and with the clear blunting of 
hypercapnic reactivity in the present study.  
This provided the opportunity to determine whether it might contribute to ventilatory 
changes associated with increasing Tc during exercise.  To do this, we used both steady state 
exercise at an intensity below the (first) metabolic threshold, as well as incremental exercise 
with and without INDO. 
 
Core temperature and heart rate were not different pre resting period (Table 1). Post 
ingestion heart rate was significantly decreased with INDO during the resting period, which 
was expected, as observed by (Bradford et al., 2008), and necessary for normal regulation of 
arterial blood pressure (Table 2).  The likely causation of the reduced heart rate is via PG 
mediation driving vasoconstriction, subsequently increasing mean arterial pressure, and 
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causing reduced cardiac output need, hence a reduction in heart rate. Whilst Tc had a trivial 
change, its likely INDO did not alter central effectors during rest. 
Training status had no effect on altered response to INDO ingestion. This was clearly 
evident with the main aletrations being MCAv (Figure 2), PETCO2 (Figure 5) and heart rate 
(Figure 6) all decline across participants. Interestingly there was not a reliable presence of 
thresholds, in which lead to not being able to formally test ventilation responses and training 
status. 
 
5.2 STEADY STATE EXERCISE  
 
The commencement of exercise drove an increase in MCAv with a more substantial 
relative rise in CONTROL whilst a subdued response occurred in INDO (Figures 7 & 8), and 
this was consistent across all participants.  The increase in MCAv was expected with exercise 
as discussed in previous research, highlighting the effect moderate exercise has on MCAv 
(Secher et al., 2008; Wiley et al., 2015; and Smith et al., 2016), The initial rise of MCAv 
during exercise onset appears to be driven by cortical activation and hence demand, blood 
pressure, stroke volume and cardiac output, and a small rise in PetCO2 arising from muscle 
activation.  It is likely therefore that the reduced rise in MCAv with INDO, is due to PG-
mitigation.  
As exercise continued, Control and INDO interestingly matched relative change in 
MCAv, from the pre-exercising values coupled with the same absolute rise in Tc (Figure 7).  
It would appear that whilst absolute MCAv remained lower across all time periods with 
INDO.  This suggests that whilst PG mediation was altered via exercise onset represented by 
relative and absolute increase in MCAv the effect INDO had on the endothelial cells was still 
strong enough to rebuff drivers and had little effect on exercise tolerance or response to 
exercise.  This does somewhat seem counterintuitive, and we would have expected to see 
reduced exercise capacity or tolerance, however in both conditions recorded perceived 
exertion was never reported higher than “somewhat hard” (Figure 15), whilst exercising time 
was similar between trials (Figure 14), suggesting that whilst flow was reduced, adequate 






This study found no clear threshold during initial rise of Tc in either INDO or 
CONTROL, as represented by VE alongside other parameters (V̇E/ V̇CO2, V̇E/ V̇O2, breath 
frequency, tidal volume and respiratory rate (Table 3).  This was unexpected as Tusji et al 
(2012) observed a small rise in Tc resulted in a subtle upregulation of VE.  Further 
examination of Tusji et al, (2012) found the two fitter participants had complete absence of 
the initial threshold response, suggesting that aerobic fitness could mitigate early respiratory 
change with an initial increase of Tc.  This study’s participants had a V̇O2max range of 42 – 
75 mL·kg-1·min-1, with a mean V̇O2max of 54 ± 8 mL·kg-1·min-1 whilst Tusji et al’s (2012) 
participants had a mean V̇O2max of 50 ± 6 mL·kg-1·min-1.  Whilst this study had a good 
range in aerobic ability, the mean was higher than Tusji et al (2012) and the fact that we did 
not see a clear early ventilatory threshold in participants could be due to higher average 
aerobic fitness. Interestingly Participant I did have the sharpest rise in V̇E (Figure 12) across 
both conditions and with the smallest rise in Tc.  
It is interesting to acknowledge that the VE intercept was not significantly different at 
the onset of exercise, and this the rate of change is an important consideration when 
delineating the effect MCAv may have on ventilation.  Interestingly despite significantly 
reduced MCAv during the INDO trial, ventilation response appeared to be independent of 
MCAv, as V̇E/ V̇CO2, V̇E/ V̇O2, tidal volume and respiratory rate, had non-significant 
differences in the intercepts or slopes across the exercising period (Table 3).  
A clear decline in end tidal carbon dioxide (PETCO2) was observed in the majority of 
participants (Figure 9).  This threshold occurred at a similar Tc in both conditions despite the 
vast difference in MCAv, indicating that the threshold was more than likely due to rising Tc 
and potentially feedback from muscle activation and metabolic demand.  This study 
hypothesised that MCAv would initiate a respiratory response earlier in INDO than 
CONTROL, with the premise that this was to mitigate perturbations such as rising brain 
temperature driving H+ presences, and since respiratory centres reside in the brain, a response 
would occur to reduce any further perturbations.  This studies hypothesis was null.  It appears 
that INDO decoupled MCAv from respiratory control, and any alterations in MCAv had a 





During the steady state trial INDO tended to be 0-1-0.2°C lower then CONTROL, 
until cessation point (Figure 10 & 11).  This was not an unexpected finding and supports the 
literature that NSAIDs can reduce Tc during exercise, as noted by Bradford et al, (2007).  An 
interesting observation noted the change across time was not significantly different between 
conditions (p=0.50).  This could be due to the central effects of INDO driving an increased 
sweat response via increased skin temperature, thus mitigating Tc rise, as observed by 
Bradford et al, 2007.  Paradoxically, Tc in both conditions rose at a similar rate across the 
exercising period, suggesting that the sweat rate was not different between conditions.   
Thermal perceptions and comfort were worse in INDO than CONTROL, despite Tc 
being lower in INDO trials at any given time point (Figure 15).  This potentially highlights 
that NSAID induced vasoconstriction centrally affects the sensory part of the brain in an 
attempt to stop exercise and thus reduce the strain felt by participants.  Interestingly no 
participants volitionally stopped exercise, so whilst they were uncomfortable, there was not 
enough discomfort to cause any participant to stop during the testing phase. 
 
 
5.6 RAMPED EXRCISE 
Resting MCAv was ~35 % lower in INDO (Figure 14), as expected based on the 
literature and confirmed with this study’s baseline data.  With the commencement of exercise, 
MCAv rose during the 5-min warm up, again as expected based on systemic (BP, SV, PaCO2) 
and central/downstream (cortical activation) modulators.  Furthermore, this rise was 
attenuated in INDO, presumably reflecting inhibition of PG reducing the capacity for the 
endothelial cells to relax and drive vasodilation despite strong drivers such as PaCO2 being 
present at the cell wall. Early in the incremental exercise phase, the suppression of MCAv had 
reached almost 50% and was evident in all participants (Figure 16), however the rate of change 
in MCAv per unit change in work rate, was not significantly lower in INDO across the 
specific ranges of exercise testing.  
As PaCO2 rises and falls with increasing exercise intensity, we would have expected to 
see a dampened MCAv response with INDO, thus showing little variation in MCAv across the 
ranges of exercise intensity.  This was observed with absolute MCAv being lower in INDO across 
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the exercising periods.   Surprisingly however, when comparing the relative change between 
INDO and CONTROL, they occurred at a similar rate with very trivial differences noted in the 
slopes over time (Figure 16).  
 
It was hypothesised that INDO would invoke an early ventilatory response in all 
participants when compared to CONTROL.  However the ingestion of INDO had minimal 
effect on the ventilatory thresholds, and this was regardless of fitness.  Both the initial 
threshold point (VT1 245-247 W) and subsequent secondary threshold point (VT2 326-327 
W, were not significantly different between conditions and presented at a matched intensity 
(Figure 16).  Further confirmation that MCAv had little effect on ventilation was shown in 
ramped exercise, with ventilatory equivalent being the same in both conditions, when 
measured alongside the other ventilatory parameters of breath frequency, tidal volume and 
respiratory rate; that were not significantly different between conditions (Table 3).   
Whilst ventilation appeared to respond irrespective of MCAv changes, it could be 
assumed that similar to steady state finding, Tc could be driving the ventilation response(s). 
However this was not evident in this study; whilst Tc was reduced with INDO and therefore 
started at a lower point, the mean rate of rise in response to the exercise was matched (Figure 
22), and supported by individual responses (Figure 23).  This is an interesting consideration 
and while it doesn't discount the involvement of MCAv or Tc, it does demonstrate that 
modest changes have no measurable impact.   Therefore it is important to consider other 
factors at play such as input from activated muscle and cortical activation.  It could be likely 
that the change in ventilatory response is controlled by a feed forward mechanism through 
increased cortical activation, thus driving ventilation to maintain metabolic demand.  
The absence of early threshold during the steady state trial may have been due to this 
study’s participants being of a higher aerobic capacity compared to the Tusji et al, (2012) 
participants. Interestingly, in the ramped exercise protocol, each participant achieved a 
different V̇O2max and therefore was assumed to be of a different aerobic fitness, however 
this appeared to have no significant impact on respiratory control, as the majority of 




5.2. SUMMARY  
The results of this current study indicate that whilst INDO reduced MCAv in all 
participants, the respiratory response was unaltered during rest.  This was somewhat 
expected, with the notion that during rest, any perturbations to the drivers of BBF and thus 
MCAv, were not going to be greatly affected and thus homeostatic balance would remain 
static.  Observed blunting of cerebral reactivity did occur, which was an expected finding and 
in accordance with the literature, such as Fan et al. (2011, 2012).  This decreased vasodilation 
response highlights the effect of INDO on PG inhibition within the endothelial cell and 
therefore also the vascular wall.  As predicted, a reduction in Tc was observed alongside a 
reduced HR, which is a known response to INDO and NSAID ingestion.   
Whilst we expected the response in respiratory control to be affected during exercise, 
this study’s results indicate, that INDO invoked MCAv alterations have little effect on 
respiratory control during exercise.  This study also observed that during steady state 
exercise, despite a significant reduction in MCAv (~35%), there was no clear alteration of 
respiratory control.  Further confirmation of this non-effect was shown whereby as exercise 
continued a concomitant rise in Tc occurred, and subsequently coincided with the expected 
hyperventilation, but – most importantly –this occurred at a matched absolute Tc but much 
different MCAv between each condition.  
In ramped exercise, the ever changing workload meant stabilisation of metabolic 
demands never occurred.  It is thus likely that primarily motor command but also afferent 
muscle and arterial chemical feedback and metabolic demands drove respiration, more so 
than Tc or MCAv.  This was concluded by the ventilatory thresholds (VT1 & VT2) occurring 
at very similar workloads (W), despite significantly different MCAv values and slightly 
different Tc. 
It is clear that the results gained from this study demonstrate a decoupling effect of 
MCAv from respiratory control during exercise.  This was an unpredicted and interesting 
finding.  It was originally expected that with reduced MCAv, an increase in brain temperature 
and H+ presence, may occur thus stimulating an earlier onset of respiratory response via 
central chemoreceptor and hypothalamus activation.  This appears to not have occurred and 
begs the question that global BBF needs to be further assessed to fully and completely 




Fitness status had minimal effect on the responses. A majority of participants had an 
absence of ventilaroty threshold duirng Control trials and this was suprisingly maTched in 
INDO. Futhermore, it was difficult to delinate the fitness response with trained and untrained 
particpants having maTched responses of ventilation to similar Tc increases and MCAv 
reductions. What can be concluded is whilst fitter particpants tolerated greater Tc increases 
and workloads than the less trained, the ventilatory response could not be delinated out 




 Brain blood flow (MCAv) was decoupled from respiratory control. That is, despite an 
Indomethacin-invoked reduction in MCAv, respiratory control response was similar 
between conditions. 
 Feedforward control, Tc and metabolic alterations were therefore stronger drivers of 
respiratory responses in exercise bouts, whether steady state or ramped. 
 Aerobic fitness did not have any measurable effect on these responses.  
 
5.4. LIMITATIONS AND FUTURE RESEARCH 
 
 This study observed no clear effect of BBF (MCAv) on respiratory control. However 
further investigation is warranted to determine the effect of BBF on respiratory control.  
Firstly, if redistribution of blood flow to important brain structures, such as the respiratory 
centre, located within the medulla oblongata and pons in the brainstem, occurs during times 
of reduced BBF, especially to those brain structures supplied by the vertebral artery 
(brainstem, cerebellum and the posterior hemisphere).  A study performing insonation of the 
vertebral artery, alongside MCAv, is required to determine if these older structures get a 
redistribution of BBF and how this affects respiratory control during exercise and heat.  
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 Improvements to the current study design would include altering the clothing worn by 
study participants to enable blood pressure measurements to be taken accurately with a 
device such as an automated blood pressure monitor to help establish and understand MAP 
responses.  The PVC jacket and gloves worn to mitigate heat offload, made the use of 
equipment difficult and thus measurements were unable to be taken. This study was also 
limited with incomplete data set for heart rate (during steady state exercise) and skin 
temperature due partly to human error and equipment failure. Another consideration would 
be to familiarise the participants with methods assessing hyper and hypocapnic responses.  
This study was limited by incompletion during the hypocapnic response.  If participants 
experienced in particular the hypocapnic induced response via over breathing prior to testing, 
then their tolerance to complete the protocol may increase, thus giving a higher rate of 
completion.    
Whilst this study had a higher average for V̇O2max values, a more dichotomised 
group would be beneficial in understanding fitness and thus its potential role in respiratory 
control, furthermore with the unseen early threshold, a slightly lower exercise intensity could 
be beneficial to allow for a slower rise in core temperature over time, allowing for an 
improved opportunity to see if the subtle rise in core temperature coincided with a ventilator 
change. Whilst this study only utilised V̇O2max, a more in-depth questionnaire in regards to 
frequency and type of exercise would be more representative of fitness.  These 
recommendations could help facilitate a greater understanding of brain blood flow and 
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Appendix A: (H13/062) 
27/08/2013 
The role of brain blood flow in thermoregulatory and respiratory control 
during exercise 
 
INFORMATION SHEET FOR PARTICIPANTS 
 
Thank you for showing an interest in this project.  Please read this information sheet 
carefully before deciding whether or not to participate.  If you decide to participate we thank 
you.  If you decide not to take part there will be no disadvantage to you and we thank you 
for considering our request.   
 
What is the Aim of the Project? 
 
Many of the body’s systems are controlled slightly differently in exercise than at rest, and 
are generally under more stress. The brain is at the centre of these differences. The brain’s 
environment depends on its blood flow, and this can change substantially up or down with 
various factors during exercise. The importance of brain blood flow in controlling bodily 
systems is not well known. The aims of this project are to learn more about how the brain’s 
blood flow affects the control of breathing and of body temperature during exercise, and 
whether aerobic fitness modifies these affects.  
 
Specific questions include whether: 
 Decreasing brain blood flow with Indomethacin leads to increased breathing and 
sweating responses at rest and during exercise. 
 Relatively untrained and highly fit people show similar effects of anti-inflammatory 
drugs on their brain blood flow responses and kidney filtration rates. 
The project is being undertaken as part of the requirements for a Masters of Physical 
Education degree (by Mr Matthew Shallcrass). The project will be undertaken in Lab B01 of 
the School of Physical Education, Sport and Exercise Sciences Building (55 Union St West). 
 
What Type of Participants are being sought? 
 Healthy Males and Females (trained and untrained) 
 Aged 18-45 years 
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 Relatively untrained: Have played sports involving strenuous exercise at sometime 
within the past ten years, but are currently exercising 1 to 3 times per week, and for less 
than 3 hours in total per week, OR 
 Trained: Currently doing aerobic exercise on at least 5 days per week, for a total time of 
at least 4 hours per week. 
 Prepared to undertake several sessions of maximal-effort exercise on an exercise bike in 
the laboratory, including being under some heat stress. 
 
People who have one or more of the following are requested not to participate: 
 Any disease, injury, illness or condition in which exercise is contraindicated; 
 Known or suspected diabetes, hypertension, asthma or exercise-induced asthma; 
 Currently taking or required to take any medication (other than contraception); 
 A history of venous thrombosis or any abnormality of blood clotting; 
 An allergy to, or intolerance of  Indomethacin;  
 
because, in the opinion of the researchers and the University of Otago Human Ethics 
Committee (Health), it may involve an unacceptable risk to them. 
What will Participants Do? 
After an initial introductory session, if you decide to participate, you will need to attend the 
laboratory for four sessions. 
The introductory session is for screening, and to give you an opportunity to learn more 
and decide whether you might want to be a participant. This visit should take no more 
than 90 minutes, and will consist of: 
 Filling out a medical screening questionnaire (it is important, for your own safety, 
that this is completed honestly); 
 Showing you the equipment and explaining the procedures used in the project;  
 Answering any questions that you may have regarding any aspect of the project. 
You are welcome to ask questions at any stage in this or any subsequent session. 
 Recording your height, weight, heart rate, blood pressure and blood brain flow (non-
invasively using ultrasound). 
 An aerobic fitness test - this maximal effort test will be conducted on a stationary 
cycle, while you wear a face-mask over your mouth and nose for measurement of 
how quickly you can use oxygen when at maximal effort. It is possible that, based 
on the outcome of this test, you may not be eligible to participate in the project. 
 Measuring your brain blood flow using an ultrasound device (see below), to 
determine whether a suitable signal can be obtained from you.  
 
The second and third sessions are for data collection, to examine exercise-related 
effects of standard doses of Indomethacin, relative to a placebo. These sessions will be 
separated by at least one week, and will take approximately 4 hours each.  
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These sessions will each consist of being instrumented for measurement of the following, 
which would occur before and after swallowing one of the pills mentioned above, and 
during two separate bouts of exercise: 
 brain blood flow, via ultrasound of the blood cells moving through a major artery 
supplying your brain; 
 brain oxygenation, via changes in the near infra-red light spectrum of tissue within the 
frontal region of your brain; 
  heart rate, via a chest strap which detects and records your heart’s electrical activity; 
 Deep body (core) temperature via flexible thermometers (called thermistors); one is passed 
through your nostril and swallowed down your oesophagus to a level adjacent to your 
heart. The other is inserted, by you, into your rectum. These are initially sterile thermistors, 
which you reuse between the sessions after they have been deep disinfected, and which are 
then discarded following the project;  
  skin temperatures via thermistors taped to the skin at six sites: forehead, chest, abdomen, 
scapula, dorsal forearm, dorsum of the fifth finger, anterior thigh and posterior leg; 
 Rate of sweating, via small Perspex capsules glued on your arm and forehead; 
 Blood pressure, via a cuff worn on one finger; 
 Blood levels of inflammatory chemicals (called cytokines), lactate, and a chemical that 
passes into your urine (creatinine); 
 Urine, for its volume and overall concentration of particles, as a measure of your hydration,  
and the amount of creatinine which has come from your blood, to indicate how your 
kidneys are working; 
 Your Perceptions of your body temperature and your level of exertion; 
 Your brain blood vessels’ health (responsiveness), as indicated from their sensitivity to 
changes in carbon dioxide levels in your blood and how brain blood flow is regulated 
during changes in blood pressure. The first test requires you to breathe higher-than-normal 
levels of carbon dioxide (5 & 7%) for up to 5 minutes, which may cause a slight feeling of 
breathlessness, and then to over-breathe for 3 minutes to reduce carbon dioxide levels in 
your blood. We will ask you to then perform a series of repeated stand-squats (10-s squat, 
10-s stand) for 5 min. This protocol causes rapid changes in blood pressure (e.g., ~35  mm 
Hg) from which we can use to assess how well your brain blood flow is regulated. 
The first bout of exercise is performed after a brief stint with your legs in a cool bath to 
lower body temperature slightly. Exercise involves cycling at a reasonably easy intensity, 
but with extra clothing on to make you heat up, and will ultimately stop because you feel too 
hot or we believe that you are too hot; whichever occurs first. After being cooled with your 
legs in the bath, you will complete a second bout of exercise, which will feel like a repeat of 
the aerobic fitness test, but you will stop before becoming exhausted. You will then be 
cooled again in the bath, then the instruments will be removed, and the session complete. 
 
Can Participants Change their Mind and Withdraw from the Project? 
Yes. You may withdraw from participation project at any time and without any disadvantage 




Risks and Benefits of Participation. 
Benefits potentially include: 
 Learning your aerobic fitness and having an extensive physiological assessment 
undertaken during prolonged cycling. 
 Contributing to the development of knowledge on how people achieve control of 
their body temperature and breathing, especially during exercise. 
 
Risks include: 
 Ingesting Indomethacin: Apart from the possibility of choking on the pills, it remains 
possible that long-term use of drugs which block inflammatory processes may 
ultimately increase risk of cardiovascular disease. 
 Exercise: Maximal-effort cycling is uncomfortable, and will perhaps be painful (i.e., 
during the fitness test and the ramped protocol). 
 Cardiovascular injury (heart attack or stroke) is approximately twice as likely to occur 
during exercise compared with rest. Participants being used in this study are at low risk 
of such injury, but are not at no risk. 
 Break down of muscle tissue (Rhabdomyolysis) can result from prolonged high 
intensity exercise and factors such as heat exposure. Elevations of core temperature will 
be continually measured, with a maximal allowable level of 39°C and 39.5°C 
(Oesophegeal) allowed for untrained and trained participants, respectively, beyond 
which exercise would be terminated. 
 Blood samples: Aside from the brief pain experienced by the venous puncture or finger 
prick risks include bruising or cross contamination. Appropriate procedures will be 
followed, by trained personnel, which greatly reduces but does not completely prevent 
any such risks. 
 Ultrasound: It is well established that ultrasound has the potential to cause adverse 
effects in experimental animals, but whether similar effects also occur with humans in 
susceptible tissue (e.g., neural) in the doses used in experiments such as this requires 
further investigation. After more than a decade of ultrasound imaging in regional 
analgesia and in pain medicine interventions, there are no major reports of harm 
secondary to its use (Anesthesiology, 115(5), 1109-1124, 2011). 
 Oesophageal and rectal thermistors: Participants may find discomfort with some 
aspects of data collection.  The thermistors used to measure core temperature are 
flexible, 4 mm in diameter, and disposable. Inserting the thermistors may (but doesn’t 
usually) cause some initial physical discomfort, and any discomfort should disappear as 
soon as insertion is complete. Thermistors will be chemically disinfected between 
sessions and only reused for a given participant, before being disposed of in biohazard 
waste following the study. All disinfection and storage of thermistors will be conducted 
at the School of Physical Education, Sport and Exercise Sciences, University of Otago. 
Data Information collected 
 Name and phone number: For contact reasons.   
 Age and training details: For screening and group characterisation purposes. 
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 Maximal aerobic power: To base endurance workloads on and to statistically 
quantify group characteristics. 
 Physiological function and perceptions at rest and during exercise and recovery, as 
detailed above.  
Confidentiality:  
All data obtained will be used solely for the purposes described above. The data collected will 
be securely stored in such a way that only those mentioned below will be able to gain access 
to it.  Data obtained as a result of the research will be retained for at least 5 years in secure 
storage. Any personal information held on participants [name, age, phone number] will be 
destroyed at the completion of the research. 
The results of the project may be published, reported in a scientific conference, and reported 
in a Masters dissertation, which will be available in the University of Otago Library (Dunedin, 
New Zealand), but your anonymity will be preserved. 
In any such reporting, the data included will not be linked to a specific participant. Your data 
will be assigned a personal identification number to ensure anonymity in both the analysis and 
documentation of results. The personal data will be accessible only by the researchers. 
Compensation for injury: 
In the unlikely event of a physical injury as a result of your participation in this study, you 
will be covered by the accident compensation legislation with its limitations. If you have any 
questions about ACC please feel free to ask the researcher for more information before you 
agree to take part in this trial. 
Contact Information 
Please feel free to contact us at any time with questions and concerns you may have about 
participating in this research study. 
Matt Shallcrass     Assoc Prof Jim Cotter 
School of Physical Education, Sport and   School of Physical Education, Sport 
and 
Exercise Sciences    Exercise Sciences 
Telephone: 027 655 4545    Telephone: (03)479 9109 
Email: matt.shallcrass@gmail.com  Email: jim.cotter@otago.ac.nz   
 
Dr Sam Lucas     Prof Rob Walker 
Department of Physiology   Department of Medicine 
Email: sam.lucas@otago.ac.nz   Telephone: (03) 4740999 
      Email: rob.walker@otago.ac.nz 
 
This study has been approved by the University of Otago Human Ethics Committee 
(Health). If you have any concerns about the ethical conduct of the research you may contact 
the Committee through the Human Ethics Committee Administrator (ph. 03 479 8256).  
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APPENDIX B  
 
Appendix B: [Reference Number H13‐062]       27th August 2013 
 
The role of brain blood flow in thermoregulatory and respiratory control during exercise 
Consent Form for Participants 
 
I have read the Information Sheet concerning this project and understand what it is about.  All my 
questions have been answered to my satisfaction.  I understand that I am free to request further 
information at any stage.  
 I know that: 
1. My participation in the project is entirely voluntary; 
2. I am free to withdraw from the project at any time without any disadvantage; 
3. The data will be destroyed at the conclusion of the project but any raw data on which the 
results of the project depend will be retained in secure storage for five years, after which they will be 
destroyed; 
4. After an initial familiarisation session, I will be required to undergo a data collection session 
with a series of tests aimed at assessing the functioning of my brain blood vessels (by breathing 
higher than normal carbon dioxide levels, and performing repeated squat-to-stands), and perform 
graded levels of exercise to maximum exertion  
5. These sessions will involve measurement of my brain blood flow velocity, brain oxygenation, 
heart rate and blood pressure; 
6. Discomfort is likely during maximal-effort exercise, and such exercise has a small risk of 
cardiovascular or musculoskeletal injury; 
7. I will receive no compensation for my time; 
8.  The results of the project may be published but my anonymity will be preserved 
I agree to take part in this project. 
.............................................................................   ............................... 
       (Signature of participant)      (Date) 
This study has been approved by the University of Otago Ethics Committee. If you have any concerns about the 
ethical conduct of the research you may contact the Committee through the Human Ethics Committee 
Administrator (ph 03 479 8256). Any issues you raise will be treated in confidence and investigated and you 









1.  Have you ever fainted for an unexplained reason? (That is, for reasons other than a fear of 
needles, the sight of something unpleasant, or standing upright for too long without moving your 
legs).        Yes                           No                          
2. Do you have any cardiovascular diseases, or symptoms that might indicate cardiovascular disease 
(such as recurring chest pain, especially brought on by exercise or other forms of stress)? 
Yes                           No                         
3. Did you have a requirement to take any medications (except for contraception)? 
Yes                           No 
4. Have you suffered from any injury to your joints, muscles, ligaments or tendons, which might 
make it unsafe or unwise for you to perform maximal intensity exercise? Yes                           No 
5. Do you know of any other reason why it may not be safe for you to perform maximal intensity 
exercise?       Yes                           No 
Fitness status. 
1. Are you accustomed to undertaking strenuous exercise?    
          Yes                         No                           
2.  Across the past 2 years, on average, how many hours per week do you undertake 





APPENDIX C (continued):  EXERCISE READINESS QUESTIONNAIRE 
Health Status. 
Physical Activity Readiness Questionnaire (PAR-Q) 
PAR-Q is designed to help you help yourself.  Many health benefits are associated with regular exercise, and 
the completion of PAR-Q is a sensible first step to take if you are planning to increase the amount of physical 
activity in your life.  For most people, physical activity should not pose any problems or hazard. PAR-Q has 
been designed to identify the small number of adults for whom physical activity might be inappropriate or 
those who should have medical advice concerning the type of activity most  
 
Common sense is your best guide in answering these few questions.  Please read the carefully and check YES 
or NO opposite the question if it applies to you.  If yes, please explain. 
 
QUESTION YES NO 
 
1. Has your doctor ever said you have heart trouble? If yes, please state:  
 
2.  Do you frequently have pains in your heart and chest? If yes, please state:  
 
3.  Do you often feel fain or have spells of severe dizziness? If yes, please state:  
 
4.  Has a doctor ever said your blood pressure was too high? If yes, please state:  
 
5.  Has your doctor ever told you that you have a bone or joint problem(s), 
 
such as arthritis that has been aggravated by exercise, or might be made worse with  
 
6. Is there a good physical reason, not mentioned here, why you should not follow an  
 
activity program even if you wanted to?  If yes, please state:  
 
7. Are you or have you been pregnant in the last 6 months? 
 
8. Do you suffer from any problems of the lower back, i.e., chronic pain,  
 
9. Are you currently taking any medications?  If YES, please specify. 
 
10. Do you currently have a disability or a communicable disease?  If yes, please  
 
If you answered NO to all questions above, it gives a general indication that you may participate in physical 
and aerobic fitness activities.  The fact that you answered NO to the above questions, is no guarantee that 
you will have a normal response to exercise.   
If you answered YES to any of the above questions, then you may need written permission from a physician 
before participating in physical and aerobic fitness activities. 
 
______________________        _____________________        _____________________ 
 







How hard do you feel you are exercising? 
6  
7 Very, very light 
8  
9 Very light 
10  
11 Fairly light 
12  




17 Very hard 
18  










How does the temperature of your body feel? 
1.0 Unbearably Cold 
2.0 Extremely Cold 
3.0 Very Cold 
4.0 Cold 
5.0 Cool 
6.0 Slightly Cool 
7.0 Neutral 
8.0 Slightly Warm 
9.0 Warm 
10.0 Hot 
11.0 Very Hot 
12.0 Extremely Hot 
13.0 Unbearably Hot 
 
THERMAL COMFORT 








7.0 Very Uncomfortable 
8.0 




+5  Very good 
+4 
+3  Good 
+2 
+1  Fairly good 
 0  Neutral 
-1  Fairly bad 
-2 
-3  Bad 
-4 
-5  Very bad 
